Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events

References

• Garimella V, Cellini C. Postoperative pain control. Clin Colon Rectal Surg. 2013;26(3):191–196.
   PubMed Web of Science ®Google Scholar
• Gan TJ, Epstein RS, Leone-Perkins ML, et al. Practice patterns and treatment challenges in acute postoperative pain management: a survey of practicing physicians. Pain Ther. 2018;7(2):205–216.
   PubMed Web of Science ®Google Scholar
• Small C, Laycock H. Acute postoperative pain management. Br J Surg. 2020;07(2):e70–e80.
   Google Scholar
• Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011;17:S276–87.
   PubMedGoogle Scholar
• Shafi S, Collinsworth AW, Copeland LA, et al., Association of opioid-related adverse drug events with clinical and cost outcomes among surgical patients in a large integrated health care delivery system. JAMA Surg. 153(8): 757–763. 2018.
   PubMed Web of Science ®Google Scholar
• Yang R, Wolfson M, Lewis MC. Unique aspects of the elderly surgical population: an anesthesiologist’s perspective. Geriatr Orthop Surg Rehabil. 2011;2(2):56–64.
   PubMedGoogle Scholar
• Ri M, Aikou S, Seto Y. Obesity as a surgical risk factor. Ann Gastroenter Surg. 2017;2(1):13–21
   PubMed Web of Science ®Google Scholar
• Simpson KN, Fossler MJ, Wase L, et al., Cost-effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain. J Comp Eff Res. 10(15): 1107–1119. 2021.
   PubMed Web of Science ®Google Scholar
• Viscusi ER, Skobieranda F, Soergel DG, et al. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the mu-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res. 2019;12:927–943.
   PubMed Web of Science ®Google Scholar
• Singla NK, Skobieranda F, and Soergel DG, et al. APOLLO-2: a randomized, placebo and active-controlled phase III study investigating oliceridine (TRV 130), a G protein–biased ligand at the μ-opioid receptor, for management of moderate to severe acute pain following abdominoplasty. Pain Pract. 2019;19(7):715–731.
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. FDA approves new opioid for intravenous use in hospitals, other controlled clinical settings [media release]. August 26, 2020. [cited 2021 July 22]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-opioid-intravenous-use-hospitals-other-controlled-clinical-settings
   Google Scholar
• DeWire SM, Yamashita DS, and Rominger DH, et al. A G protein-biased ligand at the μ -opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344(3):708–717.
   PubMed Web of Science ®Google Scholar
• Bohn LM, Lefkowitz RJ, Gainetdinov RR, et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science. 1999;286(5449):2495–2498.
   PubMed Web of Science ®Google Scholar
• Raehal KM, Walker JK, Bohn LM. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther. 2005;314(3):1195–1201.
   PubMed Web of Science ®Google Scholar
• Bergese SD, Brzezinski M, Hammer GB, et al. ATHENA: a phase 3, open-label study of the safety and effectiveness of oliceridine (TRV130), a G-protein selective agonist at the µ-opioid receptor, in patients with moderate to severe acute pain requiring parenteral opioid therapy. J Pain Res. 2019;12:3113–3126.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231–250.
   PubMed Web of Science ®Google Scholar
• Morrison B, Kelliher L, Jones C. The economic benefits of enhanced recovery after surgery programmes. Digestive Med Res. 2019. 2:20.
   Google Scholar
• US Department of Health and Human ServicesMorrison B, Kelliher L, and Jones C. Agency for Healthcare Research and Quality (AHRQ). The Healthcare Cost and Utilization Project (HCUP), National (Nationwide) Inpatient Sample (NIS) dataset. [cited 2021 July 22]. https://hcupnet.ahrq.gov/
   Google Scholar
• Khanna AK, Bergese SD, Jungquist CR, et al. Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: an international prospective, observational trial. Anesth Analg. 2020;131(4):1012–1024.
   PubMed Web of Science ®Google Scholar
• Oderda GM, Senagore AJ, Morland K, et al. Opioid-related respiratory and gastrointestinal adverse events in patients with acute postoperative pain: prevalence, predictors, and burden. J Pain Palliat Care Pharmacother. 2019;33(3–4):82–97.
   PubMed Web of Science ®Google Scholar
• Rao VK, Khanna AK. Postoperative respiratory impairment is a real risk for our patients: the intensivist’s perspective. Anesthiol Res Pract. 2018: 3215923
   Google Scholar
• Khanna AK, Saager L, Bergese SD, et al. Opioid-induced respiratory depression increases hospital costs and length of stay in patients recovering on the general care floor. BMC Anesthesiol. 2021;21(1):88.
   PubMed Web of Science ®Google Scholar
• Saager L, Jiang W, and Khanna AK, et al. Respiratory depression on general care floors increases cost of care: results from the PRODIGY Trial. Abstract 2242. In: Anesthesiology 2019 Meeting. October 19–23, 2019. Orlando, Florida. [cited 2021 July 22]. Available from: http://www.asaabstracts.com/strands/asaabstracts/abstract.htm?year=2019&index=17&absnum=1858
   Google Scholar
• Hill RP, Lubarsky DA, Phillips-Bute B, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiol. 2000;92(4):958–967.
   PubMed Web of Science ®Google Scholar
• Phillips C, Brookes CD, Rich J, et al. Postoperative nausea and vomiting following orthognathic surgery. Int J Oral Maxillofac Surg. 2015;44(6):745–751.
   PubMed Web of Science ®Google Scholar
• Gan TJ, Wase L. Oliceridine, a G protein-selective ligand at the μ-opioid receptor, for the management of moderate to severe acute pain. Drugs Today (Barc). 2020;56(4):269–286.
   PubMed Web of Science ®Google Scholar
• Barra M, Remák E, Liu DD, et al. A cost-consequence analysis of parecoxib and opioids vs opioids alone for postoperative pain: chinese perspective. Clinicoecon Outcomes Res. 2019;11:169–177.
   PubMed Web of Science ®Google Scholar
• Echeverria-Villalobos M, Stoicea N, Todeschini AB, et al. Enhanced recovery after surgery (ERAS): a perspective review of postoperative pain management under ERAS pathways and its role on opioid crisis in the United States. Clin J Pain. 2020;36(3):219–226.
   PubMed Web of Science ®Google Scholar
• Maheshwari K, Avitsian R, Sessler DI, et al. Multimodal analgesic regimen for spine surgery: a randomized placebo-controlled trial. Anesthesiology. 2020;132(5):992–1002.
   PubMed Web of Science ®Google Scholar
• Bernstein J, Feng J, Mahure S, et al. Revision total knee arthroplasty is associated with significantly higher opioid consumption as compared with primary total knee arthroplasty in the acute postoperative period. Arthroplast Today. 2020;6(2):172–175.
   PubMedGoogle Scholar
• Verret M, Lauzier F, Zarychanski R, et al. Perioperative use of gabapentinoids for the management of postoperative acute pain: a systematic review and meta-analysis. Anesthesiology. 2020;133(2):265–279.
   PubMed Web of Science ®Google Scholar
• Beloeil H, Garot M, and Lebuffe G, et al. Balanced opioid-free anesthesia with dexmedetomidine versus balanced anesthesia with remifentanil for major or intermediate noncardiac surgery. Anesthesiology. 2021;134(4):541–551.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Clark JD. Opioid-free anesthesia: time to regain our balance. Anesthesiology. 2021;134(4):509–514.
   PubMedGoogle Scholar
• Sadhasivam S, Chidambaran V. Pharmacogenomics of opioids and perioperative pain management. Pharmacogenomics. 2012;13(15):1719–1740.
   PubMed Web of Science ®Google Scholar
• Ayad S, Demitrack MA, Burt DA, et al. Evaluating the incidence of opioid-induced respiratory depression associated with oliceridine and morphine as measured by the frequency and average cumulative duration of dosing interruption in patients treated for acute postoperative pain. Clin Drug Invest. 2020;40(8):992–1002.
   Web of Science ®Google Scholar
• Beard TL, Michalsky C, Candiotti KA, et al. Oliceridine is associated with reduced risk of vomiting and need for rescue antiemetics compared to morphine: exploratory analysis from two Phase 3 randomized placebo and active controlled trials. Pain Ther. 2021;10(1):541–551.
   Web of Science ®Google Scholar
• Hug BL, Keohane C, Seger DL, et al. The costs of adverse drug events in community hospitals. Jt Comm J Qual Patient Saf. 2012;38(3):120–126.
   PubMedGoogle Scholar